Search results
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 6 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 5 days agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day ago- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase ...
British patients test world’s first personalised MRNA cancer jab for melanoma
The Independent via Yahoo News· 5 days agoPhase 2 trial data, published in December, found that people with serious high-risk melanomas who...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 7 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows ...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 6 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Man’s ‘bump on head’ turns out to be sign of skin cancer
Yahoo Life UK· 5 days agoYoung says he feels 'excited' to be trialling the new vaccine. (PA) PA Phase 2 data, published in...
BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024
Digital Journal· 7 days ago"We are very pleased to be chosen to present data from our two lead candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FccgRIIB) at ASCO 2024. Our research suggests that each of these first-in-class ...
GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate...
FOX 8 Cleveland· 7 days agoGV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and cancer biology to create next-generation antibody therapeutics, today announced the publication of a peer-reviewed ...
UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda
Reuters via Yahoo Finance· 6 days agoMerck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling ...